[HTML][HTML] Inhibition of TPL2 by interferon-α suppresses bladder cancer through activation of PDE4D
Z Qiang, Z Zhou, T Peng, P Jiang, N Shi… - Journal of Experimental …, 2018 - Springer
Background Drugs that inhibit the MEK/ERK pathway have therapeutic benefit in bladder
cancer treatment but responses vary with patients, for reasons that are still not very clear …
cancer treatment but responses vary with patients, for reasons that are still not very clear …
Inhibition of TPL2 by interferon-α suppresses bladder cancer through activation of PDE4D
Z Qiang, Z Zhou, T Peng, P Jiang, N Shi… - Journal of Experimental …, 2018 - infona.pl
Background Drugs that inhibit the MEK/ERK pathway have therapeutic benefit in bladder
cancer treatment but responses vary with patients, for reasons that are still not very clear …
cancer treatment but responses vary with patients, for reasons that are still not very clear …
Inhibition of TPL2 by interferon-α suppresses bladder cancer through activation of PDE4D.
Z Qiang, ZY Zhou, T Peng, PZ Jiang, N Shi… - … of Experimental & …, 2018 - europepmc.org
Background Drugs that inhibit the MEK/ERK pathway have therapeutic benefit in bladder
cancer treatment but responses vary with patients, for reasons that are still not very clear …
cancer treatment but responses vary with patients, for reasons that are still not very clear …
Inhibition of TPL2 by interferon-[alpha] suppresses bladder cancer through activation of PDE4D
Z Qiang, Z Zhou, T Peng, P Jiang, N Shi… - … of Experimental & …, 2018 - go.gale.com
Background Drugs that inhibit the MEK/ERK pathway have therapeutic benefit in bladder
cancer treatment but responses vary with patients, for reasons that are still not very clear …
cancer treatment but responses vary with patients, for reasons that are still not very clear …
Inhibition of TPL2 by interferon-α suppresses bladder cancer through activation of PDE4D
Z Qiang, ZY Zhou, T Peng, PZ Jiang… - … of experimental & …, 2018 - pubmed.ncbi.nlm.nih.gov
Background Drugs that inhibit the MEK/ERK pathway have therapeutic benefit in bladder
cancer treatment but responses vary with patients, for reasons that are still not very clear …
cancer treatment but responses vary with patients, for reasons that are still not very clear …
Inhibition of TPL2 by interferon-α suppresses bladder cancer through activation of PDE4D
Z Qiang, Z Zong-yuan, T Peng, P Jiang… - … of Experimental and …, 2018 - search.proquest.com
Background Drugs that inhibit the MEK/ERK pathway have therapeutic benefit in bladder
cancer treatment but responses vary with patients, for reasons that are still not very clear …
cancer treatment but responses vary with patients, for reasons that are still not very clear …
[PDF][PDF] Inhibition of TPL2 by interferon-α suppresses bladder cancer through activation of PDE4D
Z Qiang, Z Zhou, T Peng, P Jiang, N Shi, EM Njoya… - 2018 - scholar.archive.org
Background: Drugs that inhibit the MEK/ERK pathway have therapeutic benefit in bladder
cancer treatment but responses vary with patients, for reasons that are still not very clear …
cancer treatment but responses vary with patients, for reasons that are still not very clear …
[HTML][HTML] Inhibition of TPL2 by interferon-α suppresses bladder cancer through activation of PDE4D
Z Qiang, Z Zhou, T Peng, P Jiang… - … of Experimental & …, 2018 - jeccr.biomedcentral.com
Drugs that inhibit the MEK/ERK pathway have therapeutic benefit in bladder cancer
treatment but responses vary with patients, for reasons that are still not very clear. Interferon …
treatment but responses vary with patients, for reasons that are still not very clear. Interferon …
[HTML][HTML] Inhibition of TPL2 by interferon-α suppresses bladder cancer through activation of PDE4D
Z Qiang, Z Zhou, T Peng, P Jiang, N Shi… - … of Experimental & …, 2018 - ncbi.nlm.nih.gov
Background Drugs that inhibit the MEK/ERK pathway have therapeutic benefit in bladder
cancer treatment but responses vary with patients, for reasons that are still not very clear …
cancer treatment but responses vary with patients, for reasons that are still not very clear …
[PDF][PDF] Inhibition of TPL2 by interferon-α suppresses bladder cancer through activation of PDE4D
Z Qiang, Z Zhou, T Peng, P Jiang, N Shi, EM Njoya… - 2018 - aps.pharmi.uz
Background: Drugs that inhibit the MEK/ERK pathway have therapeutic benefit in bladder
cancer treatment but responses vary with patients, for reasons that are still not very clear …
cancer treatment but responses vary with patients, for reasons that are still not very clear …